Mechanical circulatory support with extracorporeal life support (ECLS) can be considered as a bridge for patients with pulmonary arterial hypertension (PAH) and right ventricular (RV) failure. ECLS configurations like veno-venous ECMO can provide pulmonary support and veno-arterial ECMO can provide both pulmonary and cardiac support. Dynamic adjustments to PAH medications are required during ECLS due to changes in pharmacokinetics. ECLS can bridge patients to recovery if the RV failure is acute and reversible or to lung transplant if the patient is a transplant candidate. Experienced centers may have better outcomes with ECLS for PAH and RV failure.
This document discusses the pathophysiology and treatment of acute pulmonary embolism (PE). It covers:
- The pathophysiological effects of PE on right ventricular function and hemodynamics.
- Clinical prediction rules and diagnostic strategies for PE including D-dimer testing and imaging modalities like CT, VQ scan, and angiography.
- Treatment options for PE including anticoagulants like heparin, low molecular weight heparin, fondaparinux, and newer oral agents; as well as thrombolytics, vena cava filters, and embolectomy. LMWH is recommended as first-line treatment due to superior safety compared to unfractionated heparin
The document discusses the management of massive pulmonary embolism (PE), which is defined as PE with systolic blood pressure ≤90 mmHg or a pressure drop of >40 mmHg for 15 minutes. It describes evaluating patients for right ventricular dysfunction using CT, echocardiogram, or biomarkers. For confirmed massive PE, initial treatment involves heparin, supportive care, and consideration of thrombolysis which reduces mortality compared to heparin alone but risks bleeding. Catheter-directed thrombolysis or surgical embolectomy are alternatives if thrombolysis is contraindicated or fails.
The document discusses the management of massive pulmonary embolism (PE), which is defined as PE with systolic blood pressure ≤90 mmHg or a pressure drop of >40 mmHg for 15 minutes. Initial treatment involves oxygen, pain control, and cautious IV fluids. If PE is confirmed on CT or echocardiogram, thrombolytics are given if not contraindicated. For patients who fail or cannot receive thrombolytics, catheter-based thrombolysis or surgical embolectomy are options. The risks and diagnostic alternatives of renal failure are also covered.
The document discusses patient selection and management for pediatric and adult extracorporeal membrane oxygenation (ECMO). ECMO is considered for acute, life-threatening respiratory or cardiac conditions that are potentially reversible and unresponsive to conventional therapies. Younger age, fewer days on ventilation pre-ECMO, and better oxygenation predict survival. Venovenous ECMO is preferred over venoarterial when possible. Management involves lung rest through ventilator optimization, maintenance of adequate oxygenation and circulation, and treatment of complications like bleeding and infection during the ECMO run. Weaning and decannulation criteria include clinical and radiographic improvement allowing reduction and then discontinuation of ECMO support.
The document discusses the process and objectives of pre-anesthesia checkups (PACs). A PAC involves assessing a patient's medical history, conducting a physical exam, and developing an anesthesia plan. It aims to evaluate perioperative risk and ensure a patient can safely tolerate anesthesia. Key parts of the evaluation include reviewing the cardiovascular, respiratory, and other organ systems, as well as performing airway exams and risk assessments. The PAC provides important information to inform anesthesia management and optimize patient safety and outcomes.
Low dose dopamine increases GFR and RBF. The DAD-HF trial investigated 60 patients randomized to low dose furosemide (continuous infusion 0.5 mg/kg/day) with or without low dose dopamine (2 μg/kg/min). Dopamine preserved renal function compared to furosemide alone in patients with acute decompensated heart failure. There were no significant differences found in a trial comparing high vs low dose furosemide or bolus vs continuous infusion on renal function or symptoms. Novel agents targeting fluid overload, renal function, contractility, and vasomotion may provide new therapeutic options for acute heart failure.
Prof. U. C. SAMAL provides an overview of acute decompensated heart failure and what is new in the field. He discusses similarities and differences between acute myocardial infarction and acute heart failure syndromes. Mortality rates are high for both conditions, though clinical benefits of interventions are greater for acute MI based on published clinical trials. The document then discusses definitions and classifications of acute heart failure syndromes, as well as guidelines for diagnosis and treatment from ESC and ACC/AHA. Biomarkers that can help with diagnosis, prognosis, and guiding therapy are also summarized.
This document discusses the pathophysiology and treatment of acute pulmonary embolism (PE). It covers:
- The pathophysiological effects of PE on right ventricular function and hemodynamics.
- Clinical prediction rules and diagnostic strategies for PE including D-dimer testing and imaging modalities like CT, VQ scan, and angiography.
- Treatment options for PE including anticoagulants like heparin, low molecular weight heparin, fondaparinux, and newer oral agents; as well as thrombolytics, vena cava filters, and embolectomy. LMWH is recommended as first-line treatment due to superior safety compared to unfractionated heparin
The document discusses the management of massive pulmonary embolism (PE), which is defined as PE with systolic blood pressure ≤90 mmHg or a pressure drop of >40 mmHg for 15 minutes. It describes evaluating patients for right ventricular dysfunction using CT, echocardiogram, or biomarkers. For confirmed massive PE, initial treatment involves heparin, supportive care, and consideration of thrombolysis which reduces mortality compared to heparin alone but risks bleeding. Catheter-directed thrombolysis or surgical embolectomy are alternatives if thrombolysis is contraindicated or fails.
The document discusses the management of massive pulmonary embolism (PE), which is defined as PE with systolic blood pressure ≤90 mmHg or a pressure drop of >40 mmHg for 15 minutes. Initial treatment involves oxygen, pain control, and cautious IV fluids. If PE is confirmed on CT or echocardiogram, thrombolytics are given if not contraindicated. For patients who fail or cannot receive thrombolytics, catheter-based thrombolysis or surgical embolectomy are options. The risks and diagnostic alternatives of renal failure are also covered.
The document discusses patient selection and management for pediatric and adult extracorporeal membrane oxygenation (ECMO). ECMO is considered for acute, life-threatening respiratory or cardiac conditions that are potentially reversible and unresponsive to conventional therapies. Younger age, fewer days on ventilation pre-ECMO, and better oxygenation predict survival. Venovenous ECMO is preferred over venoarterial when possible. Management involves lung rest through ventilator optimization, maintenance of adequate oxygenation and circulation, and treatment of complications like bleeding and infection during the ECMO run. Weaning and decannulation criteria include clinical and radiographic improvement allowing reduction and then discontinuation of ECMO support.
The document discusses the process and objectives of pre-anesthesia checkups (PACs). A PAC involves assessing a patient's medical history, conducting a physical exam, and developing an anesthesia plan. It aims to evaluate perioperative risk and ensure a patient can safely tolerate anesthesia. Key parts of the evaluation include reviewing the cardiovascular, respiratory, and other organ systems, as well as performing airway exams and risk assessments. The PAC provides important information to inform anesthesia management and optimize patient safety and outcomes.
Low dose dopamine increases GFR and RBF. The DAD-HF trial investigated 60 patients randomized to low dose furosemide (continuous infusion 0.5 mg/kg/day) with or without low dose dopamine (2 μg/kg/min). Dopamine preserved renal function compared to furosemide alone in patients with acute decompensated heart failure. There were no significant differences found in a trial comparing high vs low dose furosemide or bolus vs continuous infusion on renal function or symptoms. Novel agents targeting fluid overload, renal function, contractility, and vasomotion may provide new therapeutic options for acute heart failure.
Prof. U. C. SAMAL provides an overview of acute decompensated heart failure and what is new in the field. He discusses similarities and differences between acute myocardial infarction and acute heart failure syndromes. Mortality rates are high for both conditions, though clinical benefits of interventions are greater for acute MI based on published clinical trials. The document then discusses definitions and classifications of acute heart failure syndromes, as well as guidelines for diagnosis and treatment from ESC and ACC/AHA. Biomarkers that can help with diagnosis, prognosis, and guiding therapy are also summarized.
This document discusses methods for preventing deep vein thrombosis (DVT) in hospitalized patients. It describes risk factors for DVT including Virchow's triad of stasis, vessel injury, and hypercoagulability. Guidelines recommend different prophylaxis methods depending on patient risk factors and surgery type, including mechanical methods, anticoagulants, and combination approaches. Outcomes of interest include asymptomatic and symptomatic DVT and pulmonary embolism.
ICN Victoria presents Dr Aiden Burrell talking on the diagnosis, clinical features and treatment of right ventricular failure for the Intensive Care Specialist
Extracorporeal membrane oxygenation assisted cardiopulmonary resuscitation (ECPR) is an effective therapy to improve outcomes for children who experience cardiopulmonary arrest. Survival after ECLS varies between 60% and 75%. For ECPR survival is lower, with 40% to 50% of children surviving ECPR. After ECPR good neurological outcomes are seen in 40% to 60% of children. This contrasts with adult patients where neurological outcomes after ECPR are poor. Given these findings the American Heart Association has included ECPR in their 2015 guidelines for children who experience an in hospital cardiac arrest (IHCA).
The univentricular repair indications, procedures, outcomes and controversiespatacsi
This document discusses surgical options for single ventricle heart defects, including the indications, timing, and outcomes of various palliative surgeries. It describes initial procedures like pulmonary artery banding or shunting to relieve obstruction and provide pulmonary blood flow. It then discusses staged repairs like the bidirectional Glenn procedure or hemi-Fontan that redirect blood flow. Finally, it covers the modified Fontan operation, which separates systemic and pulmonary circulation without a subpulmonary ventricle. Complications, long-term outcomes, and factors affecting success are also addressed.
The univentricular repair indications, procedures, outcomes and controversiesJoel Regondola
This document discusses surgical options for single ventricle heart defects, including the indications, timing, and outcomes of various palliative surgeries. It describes initial procedures like pulmonary artery banding or shunting to relieve obstruction and provide pulmonary blood flow. It then discusses staged repairs like the bidirectional Glenn procedure or hemi-Fontan that redirect blood flow. Finally, it covers the modified Fontan operation, which separates systemic and pulmonary circulation without a subpulmonary ventricle. Complications, long-term outcomes, and factors affecting success are also addressed.
Liver transplantation & its anaesthetic managementSwadheen Rout
Liver transplantation requires careful anaesthetic management due to the extensive pathophysiological changes that occur in patients with end-stage liver disease. The three main challenges are secondary organ dysfunction, metabolic derangements, and maintaining haemodynamic stability during the complex surgery. Thorough preoperative evaluation and optimization of organ systems is essential to reduce perioperative risks. Invasive monitoring is important to guide fluid management and vasopressor use during hemodynamic fluctuations.
This document discusses potential advantages of using airway pressure release ventilation (APRV) based on experimental and clinical studies. Key advantages include: 1) APRV with spontaneous breathing can increase recruitment of dependent lung regions and decrease pulmonary shunt; 2) APRV may improve hemodynamics and organ perfusion compared to other ventilation modes; 3) APRV is associated with reduced sedative needs, less neuromuscular blockade, and improved patient and family comfort.
2017 Barcelona. Acute Cardiac Unloading and Recovery Working Group Meeting.
The Impella ventricular assist device support experience at Texas Children's Hospital.
This study reviewed the management of 1432 grown-up congenital heart disease patients over 10 years at a tertiary hospital in India. It found a early morbidity rate of 5.2% and identified previous sternotomy, emergency procedures, cross-clamp time over 45 minutes, and cyanotic disease as significant risk factors. Outcomes were generally good with a mortality rate of 1.4% and 86% follow-up completeness. However, the study was limited by its single center retrospective design and loss to follow-up of simpler cases.
The Critically Ill PAH Patient: RV SupportDuke Heart
This document discusses strategies for optimizing care of critically ill patients with pulmonary arterial hypertension (PAH), including preload optimization, afterload reduction, and use of inotropes, prostacyclin analogs, nitric oxide, and phosphodiesterase-5 inhibitors. It also covers the potential roles of balloon atrial septostomy, mechanical circulatory support such as extracorporeal membrane oxygenation, and lung transplantation. The document emphasizes the importance of a multidisciplinary team approach and consideration of palliative care/hospice in end-of-life decision making for these complex patients.
Endovascular and surgical treatment of pulmonary embolism 26.11.17Ivo Petrov
Interventional treatment (thrombus fragmentation and supraselective fibrinolysis) of high and intermediate risk patients with pulmonary embolism.
Protocols of intervention, results, clinical cases provided
This document discusses pulmonary hypertension (PH), including its definition, classification, pathophysiology, diagnosis, and management in intensive care patients. It defines PH as a mean pulmonary artery pressure >25 mmHg and outlines the various causes classified under five groups. The pathophysiology of PH involves vasoconstriction, vascular remodeling, thrombosis and endothelial dysfunction. Diagnosis involves history, physical exam, imaging like chest X-ray and ECG, as well as right heart catheterization. Management focuses on treating the underlying cause, using vasodilators, inotropes to support the right ventricle, diuretics, oxygen therapy and potentially surgery in refractory cases. PH increases mortality and deteriorations can be rapid
This document discusses pulmonary embolism (PE), including its causes, symptoms, diagnosis, and treatment. Some key points:
- PE is a common cause of preventable death, often occurring without warning signs. Prompt diagnosis and treatment are important.
- PE usually originates from blood clots that form in the deep leg veins. Symptoms can include chest pain, difficulty breathing, and syncope.
- Diagnosis is difficult as symptoms are non-specific. Imaging tests like CT scans are often needed along with blood tests like d-dimers.
- Treatment involves blood thinners to prevent further clots. Thrombolysis may be used in high-risk cases but risks need to be weighed
Rrt in icu dr said khamis zagazig april 2018 latestFarragBahbah
The document provides an overview of renal replacement therapy (RRT) modalities for critically ill patients with acute kidney injury (AKI). It discusses the history and evolution of RRT, including intermittent hemodialysis (IHD) and continuous renal replacement therapy (CRRT). The pros and cons of IHD and CRRT are presented. Key considerations for RRT include which modality to use, anticoagulation options, dialysate buffers, and membranes. Guidelines for determining therapy dose and duration and criteria for discontinuing RRT are summarized. Outcomes with IHD versus CRRT remain unclear due to limitations of existing studies. Overall, the document reviews best practices for delivering RRT to critically ill AK
The document discusses chronic thromboembolic pulmonary hypertension (CTEPH) and its pathophysiology. It describes the core pathologic process as an imbalance between prothrombotic factors and disturbed thrombus resolution, leading to in situ thrombosis over thromboembolic lesions. It also discusses the BENEFIT trial which found that treatment with bosentan improved exercise capacity and hemodynamics in inoperable CTEPH patients. The CHEST trial then evaluated riociguat, a soluble guanylate cyclase stimulator, in inoperable or recurrent CTEPH patients and found improvements in pulmonary vascular resistance and other outcomes.
This document summarizes a presentation on pulmonary embolism given in 2014. It discusses various treatment options for pulmonary embolism including heparin alone, thrombolytics, surgical embolectomy, and catheter directed therapy. It notes that guidelines support thrombolysis for massive PE but are vague on submassive PE. One study showed thrombolysis for submassive PE led to a decrease in mortality but increase in major bleeding. The presentation emphasizes treating high risk PE aggressively with a multidisciplinary team approach and considering thrombolysis or advanced procedures to reduce long term morbidity. It describes the creation of a PE advanced care team at the hospital.
This document provides an overview of the key changes and recommendations in the 2019 guidelines for pulmonary embolism (PE). Some of the major updates include: revised criteria for diagnosing PE using D-dimer tests and imaging; a new definition of high-risk PE and assessment of severity; and preference for non-vitamin K antagonist oral anticoagulants as first-line treatment in eligible patients. The guidelines also provide new algorithms for diagnosing and managing PE in pregnancy and long-term follow-up care after PE.
2019 ESC guidelines on pulmonary embolismSaitej Reddy
The document provides an overview of the updates in the 2019 guidelines for pulmonary embolism (PE) diagnosis and treatment. Key changes include adjusted D-dimer cut-off values based on age and probability; revised algorithms for diagnosing high-risk PE and assessing severity; recommending non-vitamin K antagonist oral anticoagulants as first-line treatment for eligible patients; classifying recurrence risk factors and extending treatment duration indications; and proposing a comprehensive post-PE patient follow-up algorithm. The guidelines aim to improve PE risk stratification, optimize acute care, determine chronic anticoagulation regimens, and ensure long-term management and surveillance for complications.
This document discusses methods for preventing deep vein thrombosis (DVT) in hospitalized patients. It describes risk factors for DVT including Virchow's triad of stasis, vessel injury, and hypercoagulability. Guidelines recommend different prophylaxis methods depending on patient risk factors and surgery type, including mechanical methods, anticoagulants, and combination approaches. Outcomes of interest include asymptomatic and symptomatic DVT and pulmonary embolism.
ICN Victoria presents Dr Aiden Burrell talking on the diagnosis, clinical features and treatment of right ventricular failure for the Intensive Care Specialist
Extracorporeal membrane oxygenation assisted cardiopulmonary resuscitation (ECPR) is an effective therapy to improve outcomes for children who experience cardiopulmonary arrest. Survival after ECLS varies between 60% and 75%. For ECPR survival is lower, with 40% to 50% of children surviving ECPR. After ECPR good neurological outcomes are seen in 40% to 60% of children. This contrasts with adult patients where neurological outcomes after ECPR are poor. Given these findings the American Heart Association has included ECPR in their 2015 guidelines for children who experience an in hospital cardiac arrest (IHCA).
The univentricular repair indications, procedures, outcomes and controversiespatacsi
This document discusses surgical options for single ventricle heart defects, including the indications, timing, and outcomes of various palliative surgeries. It describes initial procedures like pulmonary artery banding or shunting to relieve obstruction and provide pulmonary blood flow. It then discusses staged repairs like the bidirectional Glenn procedure or hemi-Fontan that redirect blood flow. Finally, it covers the modified Fontan operation, which separates systemic and pulmonary circulation without a subpulmonary ventricle. Complications, long-term outcomes, and factors affecting success are also addressed.
The univentricular repair indications, procedures, outcomes and controversiesJoel Regondola
This document discusses surgical options for single ventricle heart defects, including the indications, timing, and outcomes of various palliative surgeries. It describes initial procedures like pulmonary artery banding or shunting to relieve obstruction and provide pulmonary blood flow. It then discusses staged repairs like the bidirectional Glenn procedure or hemi-Fontan that redirect blood flow. Finally, it covers the modified Fontan operation, which separates systemic and pulmonary circulation without a subpulmonary ventricle. Complications, long-term outcomes, and factors affecting success are also addressed.
Liver transplantation & its anaesthetic managementSwadheen Rout
Liver transplantation requires careful anaesthetic management due to the extensive pathophysiological changes that occur in patients with end-stage liver disease. The three main challenges are secondary organ dysfunction, metabolic derangements, and maintaining haemodynamic stability during the complex surgery. Thorough preoperative evaluation and optimization of organ systems is essential to reduce perioperative risks. Invasive monitoring is important to guide fluid management and vasopressor use during hemodynamic fluctuations.
This document discusses potential advantages of using airway pressure release ventilation (APRV) based on experimental and clinical studies. Key advantages include: 1) APRV with spontaneous breathing can increase recruitment of dependent lung regions and decrease pulmonary shunt; 2) APRV may improve hemodynamics and organ perfusion compared to other ventilation modes; 3) APRV is associated with reduced sedative needs, less neuromuscular blockade, and improved patient and family comfort.
2017 Barcelona. Acute Cardiac Unloading and Recovery Working Group Meeting.
The Impella ventricular assist device support experience at Texas Children's Hospital.
This study reviewed the management of 1432 grown-up congenital heart disease patients over 10 years at a tertiary hospital in India. It found a early morbidity rate of 5.2% and identified previous sternotomy, emergency procedures, cross-clamp time over 45 minutes, and cyanotic disease as significant risk factors. Outcomes were generally good with a mortality rate of 1.4% and 86% follow-up completeness. However, the study was limited by its single center retrospective design and loss to follow-up of simpler cases.
The Critically Ill PAH Patient: RV SupportDuke Heart
This document discusses strategies for optimizing care of critically ill patients with pulmonary arterial hypertension (PAH), including preload optimization, afterload reduction, and use of inotropes, prostacyclin analogs, nitric oxide, and phosphodiesterase-5 inhibitors. It also covers the potential roles of balloon atrial septostomy, mechanical circulatory support such as extracorporeal membrane oxygenation, and lung transplantation. The document emphasizes the importance of a multidisciplinary team approach and consideration of palliative care/hospice in end-of-life decision making for these complex patients.
Endovascular and surgical treatment of pulmonary embolism 26.11.17Ivo Petrov
Interventional treatment (thrombus fragmentation and supraselective fibrinolysis) of high and intermediate risk patients with pulmonary embolism.
Protocols of intervention, results, clinical cases provided
This document discusses pulmonary hypertension (PH), including its definition, classification, pathophysiology, diagnosis, and management in intensive care patients. It defines PH as a mean pulmonary artery pressure >25 mmHg and outlines the various causes classified under five groups. The pathophysiology of PH involves vasoconstriction, vascular remodeling, thrombosis and endothelial dysfunction. Diagnosis involves history, physical exam, imaging like chest X-ray and ECG, as well as right heart catheterization. Management focuses on treating the underlying cause, using vasodilators, inotropes to support the right ventricle, diuretics, oxygen therapy and potentially surgery in refractory cases. PH increases mortality and deteriorations can be rapid
This document discusses pulmonary embolism (PE), including its causes, symptoms, diagnosis, and treatment. Some key points:
- PE is a common cause of preventable death, often occurring without warning signs. Prompt diagnosis and treatment are important.
- PE usually originates from blood clots that form in the deep leg veins. Symptoms can include chest pain, difficulty breathing, and syncope.
- Diagnosis is difficult as symptoms are non-specific. Imaging tests like CT scans are often needed along with blood tests like d-dimers.
- Treatment involves blood thinners to prevent further clots. Thrombolysis may be used in high-risk cases but risks need to be weighed
Rrt in icu dr said khamis zagazig april 2018 latestFarragBahbah
The document provides an overview of renal replacement therapy (RRT) modalities for critically ill patients with acute kidney injury (AKI). It discusses the history and evolution of RRT, including intermittent hemodialysis (IHD) and continuous renal replacement therapy (CRRT). The pros and cons of IHD and CRRT are presented. Key considerations for RRT include which modality to use, anticoagulation options, dialysate buffers, and membranes. Guidelines for determining therapy dose and duration and criteria for discontinuing RRT are summarized. Outcomes with IHD versus CRRT remain unclear due to limitations of existing studies. Overall, the document reviews best practices for delivering RRT to critically ill AK
The document discusses chronic thromboembolic pulmonary hypertension (CTEPH) and its pathophysiology. It describes the core pathologic process as an imbalance between prothrombotic factors and disturbed thrombus resolution, leading to in situ thrombosis over thromboembolic lesions. It also discusses the BENEFIT trial which found that treatment with bosentan improved exercise capacity and hemodynamics in inoperable CTEPH patients. The CHEST trial then evaluated riociguat, a soluble guanylate cyclase stimulator, in inoperable or recurrent CTEPH patients and found improvements in pulmonary vascular resistance and other outcomes.
This document summarizes a presentation on pulmonary embolism given in 2014. It discusses various treatment options for pulmonary embolism including heparin alone, thrombolytics, surgical embolectomy, and catheter directed therapy. It notes that guidelines support thrombolysis for massive PE but are vague on submassive PE. One study showed thrombolysis for submassive PE led to a decrease in mortality but increase in major bleeding. The presentation emphasizes treating high risk PE aggressively with a multidisciplinary team approach and considering thrombolysis or advanced procedures to reduce long term morbidity. It describes the creation of a PE advanced care team at the hospital.
This document provides an overview of the key changes and recommendations in the 2019 guidelines for pulmonary embolism (PE). Some of the major updates include: revised criteria for diagnosing PE using D-dimer tests and imaging; a new definition of high-risk PE and assessment of severity; and preference for non-vitamin K antagonist oral anticoagulants as first-line treatment in eligible patients. The guidelines also provide new algorithms for diagnosing and managing PE in pregnancy and long-term follow-up care after PE.
2019 ESC guidelines on pulmonary embolismSaitej Reddy
The document provides an overview of the updates in the 2019 guidelines for pulmonary embolism (PE) diagnosis and treatment. Key changes include adjusted D-dimer cut-off values based on age and probability; revised algorithms for diagnosing high-risk PE and assessing severity; recommending non-vitamin K antagonist oral anticoagulants as first-line treatment for eligible patients; classifying recurrence risk factors and extending treatment duration indications; and proposing a comprehensive post-PE patient follow-up algorithm. The guidelines aim to improve PE risk stratification, optimize acute care, determine chronic anticoagulation regimens, and ensure long-term management and surveillance for complications.
Similar to Mechanical Circulatory Support of the Failing Right Ventricle (20)
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...Donc Test
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd Edition by DeMarco, Walsh, Verified Chapters 1 - 25, Complete Newest Version TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd Edition by DeMarco, Walsh, Verified Chapters 1 - 25, Complete Newest Version TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd Edition by DeMarco, Walsh, Verified Chapters 1 - 25, Complete Newest Version Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Pdf Chapters Download Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Pdf Download Stuvia Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Study Guide Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Ebook Download Stuvia Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Questions and Answers Quizlet Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Studocu Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Quizlet Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Stuvia Community and Public Health Nursing: Evidence for Practice 3rd Edition Pdf Chapters Download Community and Public Health Nursing: Evidence for Practice 3rd Edition Pdf Download Course Hero Community and Public Health Nursing: Evidence for Practice 3rd Edition Answers Quizlet Community and Public Health Nursing: Evidence for Practice 3rd Edition Ebook Download Course hero Community and Public Health Nursing: Evidence for Practice 3rd Edition Questions and Answers Community and Public Health Nursing: Evidence for Practice 3rd Edition Studocu Community and Public Health Nursing: Evidence for Practice 3rd Edition Quizlet Community and Public Health Nursing: Evidence for Practice 3rd Edition Stuvia Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Pdf Chapters Download Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Pdf Download Stuvia Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Study Guide Questions and Answers Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Ebook Download Stuvia Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Questions Quizlet Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Studocu Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Quizlet Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Stuvia
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Mechanical Circulatory Support of the Failing Right Ventricle
1. Mechanical Circulatory Support of the
Failing Right Ventricle
Corey E. Ventetuolo, MD, MS, FAHA
Associate Professor of Medicine, Departments of Medicine, Health Services Policy & Practice
Associate Chief, Division of Pulmonary, Critical Care & Sleep Medicine
Medical Director, Adult ECLS Program
15th Annual NC Research Triangle Pulmonary Hypertension Symposium
November 17, 2023
2. Disclosures
Consultant: Regeneron, Merck, Janssen
Advisory boards: United Therapeutics, Merck, Janssen
PI, Study Co-Chair: NHLBI funded clinical trials
DSMBs: Elafin, H01/SATURN
Intellectual bias: I believe ECLS works
3. Mechanical Circulatory Support for the RV
I will not be talking about MCS for the RV in the context of LV
failure, bridge to LVAD/heart transplant, or axial flow device
Kapur, Circulation 2017
4. ECLS Alphabet Soup
ECPR: Extracorporeal CardioPulmonary
Rescusciation
VA ECMO: Veno-Arterial ExtraCorporeal
Membrane Oxygenation
VV ECMO: Veno-Venous ExtraCorporeal
Membrane Oxygenation
ECCO2R: ExtraCorporeal CO2 Removal
Triple and quadruple configurations
Modifying traditional cardiopulmonary bypass
circuit, outside of the OR
Ventetuolo & Muratore, AJRCCM 2014
5. Two Consults for PH and Extracorporeal Life Support
MICU Consult
ARDS, low tidal volume ventilation
Hemodynamically stable
TTE: severe RV dilatation, severe
dysfunction, septal flattening,
RVSP 80 mm Hg
OB/GYN Consult
30 yo connective tissue disease, 27 weeks
pregnant
Syncope
RA 15, PA 82/45/57, PAOP 2, CO TD 2.15,
PVR 26, PA sat 31%
Rudder & Ventetuolo, NEJM 2021
6. Some Caveats
Treating PH has become more complicated
Treating PH + ECLS is even more complicated, and experiential
These cases require multidisciplinary collaboration
7. ECLS in the Management of PAH:
Not a Treatment but a Bridge
To Recovery
To Destination (Transplant)
To Decision
8. Determine etiology and
transplant candidacy
Not a transplant
candidate
Transplant
candidate
ECMO as bridge to recovery ECMO as bridge to
transplant
• Progressive disease-related
decompensation despite
maximal medical therapy
• Contraindication for ECMO
• Acute decompensation due to
treatable illness
• Suboptimal medical
management
• No contraindication to ECMO
Supportive care Optimize PAH therapy
PT/OT, wean PAH
therapy
PAH with RV
failure
Adapted from Rosenzweig, ASAIO 2014
Destination first
10. PH/RV Failure and Extracorporeal Support
Cardiac support
CDH
PPHN
PAH
PE
Post-cardiotomy
Pulmonary support
Mild “secondary” PH
ARDS
VV-ECMO
ECCO2R
VA-ECMO
Alternative configurations
12. Use of ECLS to unload the RV and minimize deleterious
effects on PVR
Hypoxemia
Hypercapnia
Acidemia
Mechanical ventilation
Disselkamp, Annals ATS 2018
13. VV-ECMO: May have subtle effects on RV function
Miranda, AJRCCM 2015
13 patients with acute respiratory failure
No significant change in CI (TD)
No change in pressor requirements
10 patients with ARDS
Schmidt, Int Care Med 2013
14. Evidence that ECCO2R May be a Reasonable Approach in
Select Patients with PH/RV Failure
5 patients with AECOPD
Philipp, Muller, Int Care Med 2015
15. The REST Trial, ECCO2R
McNamee, JAMA 2021
Serious Events
31% ECCO2R vs 9% control
4.5% ICH ECCO2R group
16. Approach to RV Failure in PAH
Awake VA-ECMO
Preload: diuresis
RV ischemia: SBP>90, vasopressors
Afterload: gas exchange, PAH therapy
Contractility: inotrope
Reverse triggers: optimize MV, treat
infection
Mullin & Ventetuolo, Clin Chest Med 2021
Medical optimization
Preload: ultrafiltration
RV ischemia: stop vasopressors
Afterload: gas exchange, ± PAH
therapy
Contractility: stop inotrope
Reverse triggers: awake
17. Six month survival after BLTx 80% awake ECMO vs 50% historical
MV group (p = 0.02)
Required shorter postoperative MV and hospital LOS
12% (MV) and 27% (awake) had PAH/CTEPH as underlying
diagnosis (p=0.13)
24% (MV) and 42% (awake) had mPAP > 30 mm Hg (p=0.12)
Am J Respir Crit Care Med 2012
18. There remains clinical equipoise for the use of ECMO in
cardiogenic shock. PH/RV failure is an even larger gap.
ECLS-SHOCK ECMO-CS
Thiele, NEJM 2023
Ostadal, Circulation 2023
19. Appropriate candidate selection for VA-ECMO:
SAVE-Score
Parameters Score
Diagnosis Myocarditis +3; VT/VF +2;
post H/Ltx +3; congenital -3
Age 18-38 +7; ≥ 63 0
Weight (kg) 65-89 +2
Pre-ECMO organ failures Liver, CNS, Renal -3; CKD -6
Pre-ECMO duration intubation, hr 11-29 hrs -2; ≥ 30 hrs -4
PIP ≤ 20 mm Hg +3
Pre-ECMO cardiac arrest -2
Pre-ECMO DBP ≥ 40 mm Hg +3
Pre-ECMO pulse pressure ≤ 20mm
Hg
-2
Pre-ECMO HCO3 ≤ 15 mmol/L -3
Constant -6
Total SAVE Score -35 – +17 Schmidt, Eur Heart J 2015
There are no absolute
contraindications for ECMO
In PH, it is often bridge to decision
20. Determine etiology and
transplant candidacy
Not a transplant
candidate
Transplant
candidate
ECMO as bridge to recovery ECMO as bridge to
transplant
• Progressive disease-related
decompensation despite
maximal medical therapy
• Contraindication for ECMO
• Acute decompensation due to
treatable illness
• Suboptimal medical
management
• No contraindication to ECMO
Supportive care Optimize PAH therapy
PT/OT, wean PAH
therapy
PAH with RV
failure
Adapted from Rosenzweig, ASAIO 2014
21. Bridging to Recovery in PAH:
Possible Clinical Scenarios
PAH treatment naïve
Newly diagnosed
No parenteral therapy
Pregnant
Require surgery, procedure
Volume overload
Arrhythmia
Sepsis
Acute decompensation due to treatable illness
Suboptimal medical management
No contraindication to ECMO
Optimize PAH therapy
22. Specific Considerations for PAH Therapies During ECLS
Almost all are hepatically cleared
Lipophilic
Highly protein bound (91-99%)
Very limited data suggests highly variable levels, efficacious dosages
during ECLS
PO sildenafil in 11 neonates (Ahsman, Arch Dis Child Fetal Neonatal Ed 2010)
IV Treprostinil in 5 neonates (De Bie, Pharmacotherapy 2020)
Flow through native pulmonary circulation will impact systemic effects
Implant and explant, weaning
Circuit changes
Flow adjustments
24. Dynamic Adjustments to PAH Therapy are Required
during ECMO
Torbic, J Cardiovasc Pharmacol Ther 2022
25. Determine etiology and
transplant candidacy
Not a transplant
candidate
Transplant
candidate
ECMO as bridge to recovery ECMO as bridge to
transplant
• Progressive disease-related
decompensation despite
maximal medical therapy
• Contraindication for ECMO
• Acute decompensation due to
treatable illness
• Suboptimal medical
management
• No contraindication to ECMO
Supportive care Optimize PAH therapy
PT/OT, wean PAH
therapy
PAH with RV
failure
Adapted from Rosenzweig, ASAIO 2014
26. Alternate configurations to support PAH patients
bridging to transplant and recovery
PA-LA, 2-3.5 L/min
VV-ECMO + ASD with oxygenated shunt
Upper body VA configuration
Schmid, Ann Thorac Surg 2008
Strueber, Am J Transplant 2009
Rosenzweig, ASAIO 2014
27. Veno-pulmonary (OxyRVAD) and veno-veno-pulmonary
configurations to support the RV
Case series demonstrating possible RV
protection in severe COVID-ARDS
Case series using OxyRVAD as a bright to
LTx in PH
Concern for pulmonary overflow > high
PVR > microhemorrhage
Joyce, JTCVS 2021
Cain, J Surg Res 2021
Cain, JTCVS 2022
Mustafa, Ann Surg 2021
Lee, JHLT 2020
Usman, JCTS 2023
28. Increase in the use of prophylactic ECMO during lung
transplant, LV reconditioning in PAH
21 (42%) had post-operative LV dysfunction
26 (52%) required ECMO
Increasing use of prophylactic ECMO over study period
48/50 (96%) survived
Otto, Crit Care 2022; Tudorache,
Transplantation 2015; Pereszlenyi, Eur J
Cardio-thorac Surg, 2002; Ko, Artificial Organs
2001; Ko, Transpl Proc 1999
29. Awake ECMO after lung transplantation in PAH for LV
reconditioning
Tudorache, Transplantation 2015
Pereszlenyi, Eur J Cardio-thorac Surg, 2002
Ko, Artificial Organs 2001
Ko, Transpl Proc 1999
30. Role of ECMO in Management of PAH
IIa: Should be
considered
C: Consensus,
small/retrospective
studies
31. Experienced centers may have better outcomes
Freeman, CCM 2014
Karamlou, J Thorac Cardiovasc Surg 2013
Barbaro, Am J Respir Crtic Care Med 2015
Hayes, Am J Respir Crtic Care Med 2016
32. Two Consults for PH and Extracorporeal Life Support
MICU Consult
ARDS, low tidal volume ventilation
Hemodynamically stable
TTE: severe RV dilatation, severe
dysfunction, septal flattening,
RVSP 80 mm Hg
OB/GYN Consult
30 yo connective tissue disease, 27 weeks
pregnant
Syncope
RA 15, PA 82/45/57, PAOP 2, CO TD 2.15,
PVR 26, PA sat 31%
Rudder & Ventetuolo, NEJM 2021
VV-ECMO
or
Veno-Pulmonary
VA-ECMO
35. Take Home Points: ECLS for the Failing RV
Determine etiology and plan for bridge
Involve PH team, multidisciplinary collaboration
Beware systemic vasodilation and “recirculation”
Dynamic adjustments in PAH therapy (IV/inhaled) when BTR
Awake VA-ECMO is “standard”
Novel configurations, much more to learn, durable support may be
possible
37. Acknowledgments
Patients and families who participate in research
Funding:
AHA, 11FTF7400032
NIH, P20 GM103652
NHLBI, R01 HL141268
Parker B. Francis (Adeel Abbasi)
Brown University
James Klinger
Elizabeth Harrington
Christopher Mullin
Navneet Singh
Katherine Cox-
Flaherty
Mary Whittenhall
Britt Ferland
Kayla Thatcher
Rachel Sanders
Grayson Baird
Carsten Eickhoff
Mandy Pereira
Amy Princiotto
Adeel Abbasi
Editor's Notes
13 subjects with acute resp failure
PA catheter 6 hours after cannulation
Two patients awaiting transplant; mPAP 26 and 43 mm Hg before ECMO
No significant change in CI
No change in pressors
CI measured by TD
Acute, potentially reversible cause of moderate to severe hypoxemic respiratory failure
MV > 5 PEEP, within 48 hrs of PaO2/FiO2 < 150
Among 412 patients who were randomized (mean age, 59 years; 143 [35%] women),
405 (98%) completed the trial. The trial was stopped early because of futility and feasibility
following recommendations from the data monitoring and ethics committee. The 90-day
mortality rate was 41.5%in the lower tidal volume ventilation with extracorporeal carbon
dioxide removal group vs 39.5%in the standard care group (risk ratio, 1.05 [95%CI,
0.83-1.33]; difference, 2.0%[95%CI, −7.6%to 11.5%]; P = .68). There were significantly
fewer mean ventilator-free days in the extracorporeal carbon dioxide removal group
compared with the standard care group (7.1 [95%CI, 5.9-8.3] vs 9.2 [95%CI, 7.9-10.4] days;
mean difference, −2.1 [95%CI, −3.8 to −0.3]; P = .02). Serious adverse events were reported
for 62 patients (31%) in the extracorporeal carbon dioxide removal group and 18 (9%) in the
standard care group, including intracranial hemorrhage in 9 patients (4.5%) vs 0 (0%) and
bleeding at other sites in 6 (3.0%) vs 1 (0.5%) in the extracorporeal carbon dioxide removal
group vs the control group. Overall, 21 patients experienced 22 serious adverse events related
to the study device.
CONCLUSIONS AND RELEVANCE
The secondary outcomes are presented in Table 2. Therewere
significantly fewer ventilator-free days at day 28 in the intervention
group (7.1 [95% CI, 5.9-8.3] vs 9.2 [95% CI, 7.9-10.4]
days;meandifference,−2.1days [95%CI,−3.8to−0.3];P = .02).
There was no significant between-group difference in duration
of ventilation,needforECMOat day 7, mortality at28days,
or duration of ICU or hospital stay.
In this multicenter trial, patients with acute myocardial infarction complicated by cardiogenic shock for whom early revascularization was planned were randomly assigned to receive early ECLS plus usual medical treatment (ECLS group) or usual medical treatment alone (control group). The primary outcome was death from any cause at 30 days. Safety outcomes included bleeding, stroke, and peripheral vascular complications warranting interventional or surgical therapy.
RESULTS
A total of 420 patients underwent randomization, and 417 patients were included in final analyses. At 30 days, death from any cause had occurred in 100 of 209 patients (47.8%) in the ECLS group and in 102 of 208 patients (49.0%) in the control group (relative risk, 0.98; 95% confidence interval [CI], 0.80 to 1.19; P=0.81). The median duration of mechanical ventilation was 7 days (interquartile range, 4 to 12) in the ECLS group and 5 days (interquartile range, 3 to 9) in the control group (median difference, 1 day; 95% CI, 0 to 2). The safety outcome consisting of moderate or severe bleeding occurred in 23.4% of the patients in the ECLS group and in 9.6% of those in the control group (relative risk, 2.44; 95% CI, 1.50 to 3.95); peripheral vascular complications warranting intervention occurred in 11.0% and 3.8%, respectively (relative risk, 2.86; 95% CI, 1.31 to 6.25).
CONCLUSIONS
In patients with acute myocardial infarction complicated by cardiogenic shock with planned early revascularization, the risk of death from any cause at the 30-day follow-up was not lower among the patients who received ECLS therapy than among those who received medical therapy alone. (Funded by the Else Kröner Fresenius Foundation and others; ECLS-SHOCK ClinicalTrials.gov numb
In the ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock), immediate implementation of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) did not improve outcomes compared with no immediate VA-ECMO in patients with severe or rapidly deteriorating cardiogenic shock.
●
A large proportion (39%) of patients in the no early VA-ECMO group subsequently received VA-ECMO or other mechanical circulatory support because of further hemodynamic deterioration.
What Are the Clinical Implications?
●
Even in patients with severe or rapidly deteriorating cardiogenic shock, early hemodynamic stabilization using inotropes and vasopressors with implementation of mechanical circulatory support only in case of further hemodynamic deterioration provided outcomes that were not different from immediate insertion of VA-ECMO
Extracorporeal membrane oxygenation (ECMO) may provide mechanical pulmonary and circulatory support for patients with cardiogenic shock refractory to conventional medical therapy. Prediction of survival in these patients may assist in management of these patients and comparison of results from different centers.
AIMS:
To identify pre-ECMO factors which predict survival from refractory cardiogenic shock requiring ECMO and create the survival after veno-arterial-ECMO (SAVE)-score.
METHODS AND RESULTS:
Patients with refractory cardiogenic shock treated with veno-arterial ECMO between January 2003 and December 2013 were extracted from the international Extracorporeal Life Support Organization registry. Multivariable logistic regression was performed using bootstrapping methodology with internal and external validation to identify factors independently associated with in-hospital survival. Of 3846 patients with cardiogenic shock treated with ECMO, 1601 (42%) patients were alive at hospital discharge. Chronic renal failure, longer duration of ventilation prior to ECMO initiation, pre-ECMO organ failures, pre-ECMO cardiac arrest, congenital heart disease, lower pulse pressure, and lower serum bicarbonate (HCO3) were risk factors associated with mortality. Younger age, lower weight, acute myocarditis, heart transplant, refractory ventricular tachycardia or fibrillation, higher diastolic blood pressure, and lower peak inspiratory pressure were protective. The SAVE-score (area under the receiver operating characteristics [ROC] curve [AUROC] 0.68 [95%CI 0.64-0.71]) was created. External validation of the SAVE-score in an Australian population of 161 patients showed excellent discrimination with AUROC = 0.90 (95%CI 0.85-0.95).
CONCLUSIONS:
The SAVE-score may be a tool to predict survival for patients receiving ECMO for refractory cardiogenic shock (www.save-score.com).
Wisconsin
End-stage PH Ltx Alfred Hospital
Retrospective
LV dysfunction decrement in EF by 15%
After transplant, normalized LV preload
23 BLTx patients – severe PAH, sarcoid, IPAH, CTEPH
PVR 1400 dynes, RVEF 34%, CI 2, mPAP 66 prior
100% 90 day survival
Severe PH > LV diastolic dysfunction from small, stiff LVs > early PGD